RxDoctor Payments Data

Alisa Caliendo

Adult Health · Port Jefferson, NYNPI 1407194855

Payments from drug & device makers

$14,329in general payments, 2019–2025

Across 676 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Nestle Healthcare Nutrition Inc.$1K
  • Verona Pharma, Inc.$1K
  • QOL Medical, LLC$990
  • Takeda Pharmaceuticals U.S.A., Inc.$825
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$6655%
  • Food & beverage$13,55295%
  • Education$1111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,329 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$26,782
Medicare patients
114
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$391,594
CreonLipase/Protease/Amylase13$101,324
LinzessLinaclotide12$8,717
Famotidine219$3,382
Sucralfate27$2,388
Lansoprazole47$2,030
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,884
Esomeprazole Magnesium31$1,777
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates27$1,634
Pantoprazole Sodium106$1,628
Dicyclomine Hcl20$793
Omeprazole60$761
Methylprednisolone21$134
Doxycycline Hyclate18$105
Azithromycin11$27

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$330$391,59414 claims
AbbVieCreon, Linzess$2,034$110,04025 claims
SandozLansoprazole$16$2,03047 claims
Braintree Laboratories, Inc.Sutab$99$1,88412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.

Other adult health in Port Jefferson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →